Market news

Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.

Spruce Biosciences (SPRB) has an average rating of buy and mean price target of $148, according to a

SOUTH SAN FRANCISCO, Calif., September 08, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.

Spruce Biosciences (NASDAQ:SPRB) stock advanced 4. 1% in pre-market trading to $64 after H.

Tipranks Press Release.

SOUTH SAN FRANCISCO, Calif., August 26, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn about, and register their interest in, th

SOUTH SAN FRANCISCO, Calif., August 24, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfi

SOUTH SAN FRANCISCO, Calif., August 12, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates.

Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., July 27, 2026--Spruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior rol

Spruce Biosciences (SPRB) has an average rating of buy and mean price target of $149.71, according t

SOUTH SAN FRANCISCO, Calif., July 08, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.